Compare VFS & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VFS | IBRX |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | Vietnam | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 8.2B |
| IPO Year | 2022 | 2015 |
| Metric | VFS | IBRX |
|---|---|---|
| Price | $3.09 | $10.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $6.07 | ★ $12.75 |
| AVG Volume (30 Days) | 352.2K | ★ 10.5M |
| Earning Date | 11-20-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $113,288,000.00 |
| Revenue This Year | $57.91 | $99.26 |
| Revenue Next Year | $43.72 | $101.32 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $2.78 | $1.95 |
| 52 Week High | $5.29 | $12.43 |
| Indicator | VFS | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.17 | 69.13 |
| Support Level | $3.00 | $6.68 |
| Resistance Level | $3.27 | $12.43 |
| Average True Range (ATR) | 0.09 | 0.59 |
| MACD | -0.01 | 0.16 |
| Stochastic Oscillator | 15.05 | 90.04 |
VinFast Auto Ltd manufactures cars, and motor vehicles, renders leasing activities, trades smartphones, and related businesses. The company is engaged in designing and manufacturing premium EVs, e-scooters, and e-buses. The company's initial EV product line is an all-new range of fully electric A- through E-segment SUVs. The Company has three reportable segments, namely Car, E-scooter and Ebus. The Car segment includes the design, development, manufacturing and sales of cars and related battery lease and battery charging services for cars. The E-scooter segment includes the design, development, manufacturing and sales of e-scooters and related battery lease and battery charging service for e-scooters. The Ebus segment includes the design, development, manufacturing and sales of Ebus.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.